284 results
8-K
EX-99.2
LUMO
Lumos Pharma Inc
5 Jun 24
Lumos Pharma Announces New Analyses of Phase 2
4:09pm
of The Private Securities Litigation Reform Act of 1995. This law that, in part, gives us the opportunity to share our outlook for the future without … fear of litigation if it turns out our predictions were not correct. We are passionate about our business - including LUM-201 and the potential it may
8-K
EX-99.1
LUMO
Lumos Pharma Inc
5 Jun 24
Lumos Pharma Announces New Analyses of Phase 2
4:09pm
contained in this press release are forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. A law … that, in part, gives us the opportunity to share our outlook for the future without fear of litigation if it turns out our predictions were not correct.
We
8-K
EX-99.1
LUMO
Lumos Pharma Inc
15 May 24
Lumos Pharma Announces Positive End-of-Phase 2 Meeting with FDA and Reports First Quarter 2024 Financial Results
9:57am
contained in this press release are forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. A law that, in part … , gives us the opportunity to share our outlook for the future without fear of litigation if it turns out our predictions were not correct.
We
8-K
EX-99.2
LUMO
Lumos Pharma Inc
15 May 24
Lumos Pharma Announces Positive End-of-Phase 2 Meeting with FDA and Reports First Quarter 2024 Financial Results
9:57am
are forward- looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. This law that, in part, gives us … the opportunity to share our outlook for the future without fear of litigation if it turns out our predictions were not correct. We are passionate about our
8-K
EX-99.1
5vg fv4uajbmyy1o
18 Apr 24
Lumos Pharma Announces Abstracts Accepted for Presentation at Upcoming Medical Meetings
4:53pm
8-K
EX-99.1
zi4i2ddn5u4tfwk3 ivv
20 Mar 24
Lumos Pharma Announces that the USPTO Has Granted Patent Protection for Novel Formulation of LUM-201, Extending Exclusivity to 2042
4:27pm
8-K
EX-99.1
4ms3ir4lgi4mxfkb3 y1
7 Mar 24
Lumos Pharma Reports Full Year 2023 Financial Results and Provides Clinical Development Update
4:44pm
8-K
EX-99.2
v8filcthnbo7c7ov
7 Mar 24
Lumos Pharma Reports Full Year 2023 Financial Results and Provides Clinical Development Update
4:44pm
8-K
EX-99.1
df8vgts8ik 4de6t6e
4 Jan 24
Regulation FD Disclosure
4:34pm
8-K
EX-99.1
tunihv98a t8hs5or
15 Nov 23
Other Events
4:38pm
8-K
EX-99.1
qisgu86qhza959pi4t
7 Nov 23
Lumos Pharma Reports Third Quarter 2023 Financial Results and Clinical Development Updates
4:42pm
8-K
EX-99.1
nineqv
7 Nov 23
Lumos Pharma Announces Topline Data from Phase 2 OraGrowtH210 and OraGrowtH212 Trials of LUM-201 in PGHD
4:08pm
8-K
EX-99.2
wn7pc
7 Nov 23
Lumos Pharma Announces Topline Data from Phase 2 OraGrowtH210 and OraGrowtH212 Trials of LUM-201 in PGHD
4:08pm
8-K
EX-99.1
3jaualptv9h7aw
26 Sep 23
Lumos Pharma Announces New Data and Analysis of 15 Subjects from OraGrowtH212 Trial Presented at the 2023 ESPE Annual Meeting
4:34pm
8-K
EX-99.2
olgtxl
9 Aug 23
Lumos Pharma Reports Second Quarter 2023 Financial Results, Provides Clinical Update
4:36pm